SMS Pharmaceuticals Share Price Rise: Sector and Peer View
NiveshIQ
NSE: TORNTPHARM · Pharma
Torrent Pharmaceuticals Ltd.
₹4,965.50▲ ₹35.50 (+0.72%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on TORNTPHARM. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Torrent Pharmaceuticals Ltd.
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treatments, nutritional, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, ProZuca, and Ahaglow brands. The company was formerly known as Trinity Laboratories a
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹10,728 Cr +11.50% | ₹11,516 Cr +7.30% | ₹13,980 Cr +21.40% |
| EBITDA Margin | 31.39% | 32.31% | 31.94% |
| Net Profit | ₹1,656 Cr +33.00% | ₹1,911 Cr +15.40% | ₹2,227 Cr +16.50% |
| EPS | ₹48.94 | ₹56.45 | ₹63.92 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Torrent Pharma removes Patel, Jaiswal, Nadkarni from SMP panel
Eris, Torrent Pharma, Natco, Lupin stand out in Rs157 billion India GLP-1 opportunity: Kotak
🔒
+ 3 more stories about Torrent Pharmaceuticals Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹4, 921 Cr, PAT ₹566 Cr, EPS ₹14.87, EBITDA margin 33.6%. Growth context: revenue QoQ +17.3%, PAT QoQ +31.6%. Street verdict: inline, revenue surprise +4.2%, PAT surprise -0.3%.
Management commentary points to R&D investments and technology initiatives as the primary near-term growth lever, with e...
FY26 (last completed FY): revenue ₹13, 980 Cr, PAT ₹2, 227 Cr, EBITDA margin 31.9%, EPS ₹63.92. Year-on-year: revenue Yo...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for TORNTPHARM
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track TORNTPHARM alongside your other holdings
Unlock full TORNTPHARM research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Torrent Pharmaceuticals Ltd.?
NiveshIQ detects active intelligence signals for Torrent Pharmaceuticals Ltd. (TORNTPHARM) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Torrent Pharmaceuticals Ltd.?
Torrent Pharmaceuticals Ltd. operates in the Pharma sector with a market capitalisation of ₹18,658,945.9L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.